Bulletin from the Annual General Meeting in Bioservo Technologies AB (publ) on April 25, 2023

Bioservo AB (publ) has held its annual general meeting, whereby the meeting resolved in accordance with the Board's proposal. The complete resolution proposals are presented in the notice of the meeting.

Adoption of the income statement and balance sheet and appropriation of earnings
The Annual General Meeting approved the income statement and balance sheet included in the annual report for the financial year 2022. The meeting decided that the entire amount at the disposal of the meeting shall be carried forward.

Discharge from liability
The Annual General Meeting resolved to discharge the members of the Board of Directors and the CEO from liability for the financial year 2022.

Determination of fees for the Board of Directors and auditors
The meeting further resolved that the fees until the end of the next annual general meeting shall remain unchanged and be paid with SEK 200,000 to the chairman of the board and SEK 80,000 to each board member. Fees to the auditor shall be paid in accordance with approved invoices.

Election of the Board of Directors, Chairman of the Board and Auditor
The Meeting resolved in accordance with the proposal submitted to appoint Anders Lundmark (re-election), Runar Bjørklund (re-election), Nikolaj Sørensen (re-election), Kerstin Valinder Strinnholm (re-election) and Margit Alt Murphy PhD (re-election) as members of the Board of Directors for the period until the next Annual General Meeting. Anders Lundmark was elected Chairman of the Board. 

It was resolved in accordance with the submitted proposal to appoint Lars Kylberg, PWC (new election) as the company's auditor for the period until the next annual general meeting.

Resolution on amendment of the Articles of Association 
The Meeting resolved in accordance with the Board's proposal to amend the Articles of Association so that that the limits for the number of shares increase from a minimum of 18,000,000 shares and a maximum of 72,000,000 shares to a minimum of 28,000,000 shares and a maximum of 112,000,000 shares and that the limits for the share capital increase from a minimum of SEK 3,600,000 and a maximum of SEK 14,400,000 to a minimum of SEK 5,600,000 and a maximum of SEK 22,400,000.

In addition to the above, the Board of Directors also proposed certain editorial amendments to the Articles of Association, which were adopted by the Meeting.

Authorization to the board of directors to decide on share issues
The Meeting resolved in accordance with the Board's proposal. The board of directors shall be authorized to, on one or more occasions before the next annual general meeting, decide on a new issue of shares, issue of convertibles, issue of warrants, and/or a combination of these, so-called units. The issue may be made with or without deviation from the shareholders' preferential rights. 

The authorization shall include the right to resolve on the issue of shares, convertibles, warrants and/or units with cash payment, payment by set-off or payment in kind and otherwise be able to be associated with conditions referred to in Chapter 2, Section 5, second paragraph 1-3 and 5 of the Swedish Companies Act. 5 § second paragraph 1-3 and 5 of the Swedish Companies Act. Warrants may be issued free of charge.

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB is the company’s Certified Adviser on Nasdaq First North
For more information, please visit www.bioservo.com